Hyundai Pharmaceutical Co Ltd
KRX:004310
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hyundai Pharmaceutical Co Ltd
Change in Working Capital
Hyundai Pharmaceutical Co Ltd
Change in Working Capital Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Change in Working Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Hyundai Pharmaceutical Co Ltd
KRX:004310
|
Change in Working Capital
-₩9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-4%
|
CAGR 10-Years
2%
|
|
|
Yuhan Corp
KRX:000100
|
Change in Working Capital
-₩109B
|
CAGR 3-Years
-38%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-23%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Change in Working Capital
-₩55.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Change in Working Capital
-₩212.2B
|
CAGR 3-Years
-24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Change in Working Capital
-₩17B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-6%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Change in Working Capital
-₩21.9B
|
CAGR 3-Years
32%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
Hyundai Pharmaceutical Co Ltd
Glance View
Hyundai Pharmaceutical Co., Ltd. engages in the manufacturing and distribution of pharmaceutical products, health food drinks and medical equipment. The company is headquartered in Cheonan, Chungcheongnam-Do and currently employs 378 full-time employees. The firm mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. The company also provides dietary various beverages and medical equipment. The firm mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.
See Also
What is Hyundai Pharmaceutical Co Ltd's Change in Working Capital?
Change in Working Capital
-9B
KRW
Based on the financial report for Aug 31, 2025, Hyundai Pharmaceutical Co Ltd's Change in Working Capital amounts to -9B KRW.
What is Hyundai Pharmaceutical Co Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 10Y
2%
Over the last year, the Change in Working Capital growth was 18%.
